{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:42:42Z","timestamp":1788540162729,"version":"build-2803163510"},"reference-count":48,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/13543784.2026.2663116","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:22:43Z","timestamp":1776691363000},"page":"341-349","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Discontinued therapies for sickle cell disease: status and future directions"],"prefix":"10.1080","volume":"35","author":[{"given":"Akshay","family":"Sharma","sequence":"first","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital","place":["Memphis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Suryaprakash","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital","place":["Memphis, USA"]},{"name":"St. Jude Children\u2019s Research Hospital","place":["Memphis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza-Marie","family":"Johnson","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital","place":["Memphis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Unguru","sequence":"additional","affiliation":[{"name":"The Herman and Walter Samuelson Children\u2019s Hospital at Sinai","place":["Baltimore, USA"]},{"name":"Johns Hopkins Berman Institute of Bioethics","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"World Health Organization. Sickle-cell disease. 2025 Aug 6 [cited 2026 Jan 30]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sickle-cell-disease"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00118-7"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199505183322001"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199743"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309676"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024519"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00096-0"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2025.4749"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.06.002"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00175-3"},{"key":"e_1_3_5_17_1","unstructured":"Pfizer. Pfizer voluntarily withdraws all lots of sickle cell disease treatment OXBRYTA (voxelotor) from worldwide markets. 2024 Sep 25 [cited 2026 Jan 30]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q2147"},{"key":"e_1_3_5_19_1","unstructured":"Schneider ME. Thrown into disarray. ASH Clinical News. 2025 Feb [cited 2026 Jan 30]. Available from: https:\/\/ashpublications.org\/ashclinicalnews\/news\/8428\/Thrown-into-Disarray"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27635"},{"key":"e_1_3_5_21_1","unstructured":"Pfizer. Pfizer completes acquisition of global blood therapeutics. 2022 Oct 5 [cited 2026 Jan 30]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-completes-acquisition-global-blood-therapeutics"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015822"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brci.2025.100025"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000848800.77383.3d"},{"key":"#cr-split#-e_1_3_5_25_1.1","unstructured":"A randomized double-blind placebo-controlled multicenter study to assess the safety and efficacy of inclacumab in participants with sickle cell disease experiencing vaso-occlusive crises. ClinicalTrials.gov identifier: NCT04935879. [updated 2025 Dec 2"},{"key":"#cr-split#-e_1_3_5_25_1.2","unstructured":"cited 2026 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04935879"},{"key":"#cr-split#-e_1_3_5_26_1.1","unstructured":"A randomized double-blind placebo-controlled multicenter study of a single dose of inclacumab to reduce re-admission in participants with sickle cell disease and recurrent vaso-occlusive crises. ClinicalTrials.gov identifier: NCT04927247. [updated 2024 Dec 11"},{"key":"#cr-split#-e_1_3_5_26_1.2","unstructured":"cited 2026 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04927247"},{"key":"e_1_3_5_27_1","unstructured":"Pfizer. Pfizer provides update on phase 3 inclacumab study for the treatment of people with sickle cell disease. 2025 Aug 15. [cited 2026 Jan 30]. Available from: https:\/\/www.pfizer.com\/news\/announcements\/pfizer-provides-update-phase-3-inclacumab-study-treatment-people-sickle-cell"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00053-3"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11019-024-10223-w"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74716-7"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163725"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215643"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208623"},{"key":"e_1_3_5_34_1","unstructured":"Medicine E. Editas medicine announces strategic transition to in vivo gene editing company with intent to achieve human proof of concept in approximately two years. 2024 Dec 12 [cited 2026 Jan 30]. Available from: https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-strategic-transition-vivo-gene-editing"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.039"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-023-00480-0"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188963"},{"key":"#cr-split#-e_1_3_5_38_1.1","unstructured":"A phase I\/II study of nula-cel in autologous CD34+ hematopoietic stem cells to convert HbS to HbA for treating severe sickle cell disease. ClinicalTrials.gov identifier: NCT04819841. 2021 [updated 2025 Nov 21"},{"key":"#cr-split#-e_1_3_5_38_1.2","unstructured":"cited 2026 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04819841"},{"key":"e_1_3_5_39_1","unstructured":"Carlyle. Bluebird bio announces completion of acquisition by Carlyle and SK capital. 2025 Jun 2 [cited 2026 Jan 30]. Available from: https:\/\/www.carlyle.com\/media-room\/news-release-archive\/bluebird-bio-announces-completion-acquisition-carlyle-and-sk"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06503-x"},{"key":"e_1_3_5_41_1","unstructured":"CureDuchenne. Elevidys update. 2025 Jul 28 [cited 2026 Jan 30]. Available from: https:\/\/cureduchenne.org\/general\/elevidys-update\/"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2489123"},{"key":"#cr-split#-e_1_3_5_43_1.1","unstructured":"A phase 2\/3 randomized multicenter study of osivelotor administered orally to participants with sickle cell disease and an open-label pharmacokinetics study in pediatric participants with sickle cell disease. [updated 2025 June 17"},{"key":"#cr-split#-e_1_3_5_43_1.2","unstructured":"cited 2026 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05431088"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0034-3"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc2309497"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.10233"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2663116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:51:34Z","timestamp":1779951094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2663116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/13543784.2026.2663116"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2663116","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}